CGP 35348 hydrate, > = 97 %( NMR), solide

Non disponible en dehors du Royaume-Uni et de l'Irlande

Application

CGP 35348 hydrate has been used as a γ-aminobutyric acid-B (GABA_B) receptor inhibitor:to study its effects on intrinsic optical signal (IOS) in rat hippocampusalone or in combination with sodium salicylate to study its effects on auditory responses in the rat′s dorsal cortex of ratto study its effects on hepatocellular carcinoma cells (HCC)

Biochem/physiol Actions

CGP 35348 is a γ-aminobutyric acid-B (GABA_B) receptor antagonist. It has a higher affinity towards post-versus presynaptic receptors that can penetrate the blood-brain barrier.

Caution

Product is hygroscopic

Features and Benefits

This compound is featured on the GABAB Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

This compound is a featured product for Neuroscience research. Click here to discover more featured Neuroscience products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.

This compound was developed by Novartis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Packaging

5, 25 mg in glass bottle